Akademik Veri Yönetim Sistemi
Tezin Türü: Yüksek Lisans
Tezin Yürütüldüğü Kurum: Orta Doğu Teknik Üniversitesi, Türkiye
Tezin Onay Tarihi: 2016
Tezin Dili: İngilizce
Öğrenci: Günce Bayram
Eş Danışman: Kadri İzgü, KADRİ FATİH İZGÜ
Özet:Vulvovaginal candidiasis is a serious yeast infection that affects 80% of all women worldwide. In this study, a liposomal lyophilized powder formulation of Panomycocin was developed for therapeutic purposes against vulvovaginal candidiasis. Panomycocin is a potent antimycotic/antifungal protein secreted by Pichia anomala NCYC 434 strain previously shown to be fungicidal against Candida species which are the causal agents of vulvovaginal candidiasis. This study consists of the preparation of stratum corneum liposomes with a lipid composition identical to that of the vaginal epithelium, loading of the liposomes with Panomycocin, characterization of the liposomes and determination of biological activity of Panomycocin loaded liposomes on an in vitro human vaginal epithelium tissue model. In TEM analyses the liposomes showed size in the nano scale and regular morphology. The encapsulation and loading efficiencies of liposome nanoparticles were found as 73% and 76.8% respectively. Zeta potential measurements revealed uniform charge distribution on nanoparticle surfaces and stable nanoparticles. FTIR analyses revealed the lack of covalent interactions between encapsulated Panomycocin and liposome nanoparticles. DLS analyses showed that the nanoparticles have uniform size distribution. XRD analyses showed that they were amorphous. The liposomes released 1.71% of encapsulated Panomycocin in aqueous solution. All encapsulated Panomycocin was released when the liposomal lyophilized powder formulation was applied on in vitro human vaginal epithelium tissue model contaminated with Candida species; yielding MFC values comparable to that of pure Panomycocin. This liposomal lyophilized powder formulation of Panomycocin prepared specially with stratum corneum lipids may be subjected to further preclinical and clinical trials to develop an effective antimycotic/antifungal drug for the treatment of vulvovaginal candidiasis.